Comparative Pharmacology
Head-to-head clinical analysis: BELDIN versus LORATADINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BELDIN versus LORATADINE.
BELDIN vs LORATADINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective histamine H1 receptor antagonist; inhibits histamine-mediated allergic and inflammatory responses.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1-receptor antagonist activity. It inhibits histamine-induced vasodilation and bronchoconstriction.
1 capsule (200 mg) orally every 12 hours.
10 mg orally once daily
None Documented
None Documented
Terminal half-life: 8-12 hours (average 10 hours); prolonged in hepatic impairment (up to 24 h) and severe renal impairment (up to 18 h).
Loratadine: 8-14 hours (mean ~10 hours). Active metabolite descarboethoxyloratadine: 17-24 hours (mean ~20 hours). Clinically, duration supports once-daily dosing.
Clinical Note
moderateLoratadine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Loratadine is combined with Fluticasone propionate."
Clinical Note
moderateLoratadine + Teriflunomide
"The metabolism of Teriflunomide can be decreased when combined with Loratadine."
Clinical Note
moderateLoratadine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Loratadine."
Clinical Note
moderateLoratadine + Sulfisoxazole
Renal: 30-50% unchanged; hepatic metabolism: 50-70% (CYP3A4); biliary/fecal: 10-20%.
Approximately 40% excreted in urine as metabolites (primarily descarboethoxyloratadine) and 40% in feces as metabolites; <1% excreted unchanged.
Category C
Category A/B
Antihistamine
Antihistamine
"The metabolism of Sulfisoxazole can be decreased when combined with Loratadine."